Range Financial Group LLC Acquires 60 Shares of Eli Lilly and Company (NYSE:LLY)

Range Financial Group LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,165 shares of the company’s stock after acquiring an additional 60 shares during the quarter. Eli Lilly and Company makes up approximately 1.7% of Range Financial Group LLC’s investment portfolio, making the stock its 5th largest position. Range Financial Group LLC’s holdings in Eli Lilly and Company were worth $3,240,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in LLY. Fuller & Thaler Asset Management Inc. increased its position in Eli Lilly and Company by 7.0% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 3,054 shares of the company’s stock valued at $1,640,000 after purchasing an additional 200 shares during the period. Eagle Asset Management Inc. boosted its holdings in shares of Eli Lilly and Company by 37.2% during the 3rd quarter. Eagle Asset Management Inc. now owns 21,274 shares of the company’s stock worth $11,427,000 after buying an additional 5,772 shares in the last quarter. GSB Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 10.3% during the 3rd quarter. GSB Wealth Management LLC now owns 800 shares of the company’s stock worth $430,000 after buying an additional 75 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Eli Lilly and Company by 10.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 2,528 shares of the company’s stock worth $1,358,000 after buying an additional 244 shares in the last quarter. Finally, Paragon Private Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.9% during the 3rd quarter. Paragon Private Wealth Management LLC now owns 983 shares of the company’s stock worth $528,000 after buying an additional 37 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. Truist Financial increased their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Finally, Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $806.72.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now directly owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold 772,475 shares of company stock valued at $656,838,859 in the last ninety days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $890.62 on Tuesday. The business has a 50 day moving average of $801.37 and a 200 day moving average of $732.02. The company has a market capitalization of $846.45 billion, a price-to-earnings ratio of 131.17, a PEG ratio of 1.93 and a beta of 0.36. Eli Lilly and Company has a 1-year low of $434.34 and a 1-year high of $905.45. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.62 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 13.73 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were paid a $1.30 dividend. The ex-dividend date was Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.